证券代码：301230 证券简称：泓博医药 公告编号：2025-055 上海泓博智源医药股份有限公司 关于调整2024年限制性股票激励计划授予价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海泓博智源医药股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开第四 届董事会第四次会议，审议通过了《关于调整 2024 年限制性股票激励计划授予价格的议 案》。根据公司《上海泓博智源医药股份有限公司 2024 年限制性股票激励计划（草案）》 （以下简称"《激励计划》（草案）"或"本激励计划"）的规定及公司 2024 年第三次临 时股东大会的授权，公司董事会同意将本次激励计划授予价格由 12.35 元/股调整为 12.02 元/股。现将有关事项说明如下： 一、本次激励计划已履行的相关审批程序 （一）2024 年 10 月 31 日，公司召开第三届董事会第二十次会议，审议通过了《关于 <上海泓博智源医药股份有限公司 2024 年限制性股票激励计划（草案）>及其摘要的议案》 《关于<上海泓博智源医药股份有限公司 2024 年限制性股票激励计划 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index declined by 3.65% during the reporting period, ranking 21st among 31 primary industries, underperforming the CSI 300 index which fell by 2.73% [4][16] - The valuation of the pharmaceutical and biotechnology industry as of October 17, 2025, is a PE (TTM overall method, excluding negative values) of 30.08x, down from 31.23x in the previous period, indicating a downward trend and below the average [4][21] - Key sub-industries include vaccines (55.76x), hospitals (39.64x), and medical devices (38.84x), with the lowest valuation in pharmaceutical circulation (14.29x) [4][21] - The report highlights significant innovations presented at the 2025 ESMO conference, indicating a shift in global oncology drug development from "single-agent breakthroughs" to "combination therapy strategies" [6][8] - The newly released regulations by the State Council aim to standardize clinical research pathways, promoting innovation while ensuring safety [7][25][26] Industry Overview - The report notes that 26 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 501 million yuan, while 4 companies increased their holdings by 519 million yuan [4] - The report emphasizes the importance of monitoring third-quarter earnings to validate the fundamentals of companies, particularly those with innovative product launches and significant performance improvements [8] Important Industry News - The approval of the first domestic PDE4 inhibitor by He Mei Pharmaceutical marks a significant milestone in the industry [6][34] - The approval of a new indication for GSK's recombinant shingles vaccine expands its application to adults at increased risk due to immunodeficiency [6][36] - The U.S. Senate passed a revised version of the Biosecurity Act, which continues to impose restrictions on certain Chinese biotechnology companies [6][44] - The collaboration between Bai Li Tian Heng and BMS on the iza-bren project has reached a milestone, triggering a payment of 250 million USD [6][47] - The IPO of Xuan Zhu Biotechnology on the Hong Kong Stock Exchange saw a significant oversubscription and a substantial increase in share price during the dark trading period [6][49]

Market Overview - On October 15, the AI medical sector rose by 2.05%, with Saili Medical leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Saili Medical (603716) closed at 26.86, up 7.31% with a trading volume of 384,800 shares and a transaction value of 1.02 billion [1] - Meinian Health (002044) closed at 5.43, up 4.42% with a trading volume of 1,534,300 shares and a transaction value of 823 million [1] - Hongbo Pharmaceutical (301230) closed at 33.40, up 3.99% with a trading volume of 33,500 shares and a transaction value of 111 million [1] - Other notable stocks include Electric Science Digital (600850) up 3.79% and Yao Stone Technology (300725) up 3.45% [1] Capital Flow - The AI medical sector saw a net inflow of 189 million from institutional investors, while retail investors experienced a net outflow of 78.98 million [2][3] - Meinian Health had a net inflow of 88.56 million from institutional investors, but a net outflow of 93.20 million from retail investors [3] - Saili Medical also experienced a net inflow of 71.52 million from institutional investors, with retail investors withdrawing 32.95 million [3]

Market Overview - On September 18, the medical services sector declined by 1.68%, with Nanmo Biology leading the drop [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] Stock Performance - Notable gainers included: - Zenggansi (301257) with a closing price of 53.80, up 6.89% [1] - Yangguang Nuohuo (688621) at 79.58, up 1.38% [1] - Kanglong Huacheng (300759) at 35.70, up 0.59% [1] - Major decliners included: - Nanmo Biology (688265) at 56.16, down 5.93% [2] - Chuangxin Medical (002173) at 23.48, down 4.75% [2] - Hongbo Pharmaceutical (301230) at 36.12, down 4.06% [2] Capital Flow - The medical services sector experienced a net outflow of 2.099 billion yuan from institutional investors, while retail investors saw a net inflow of 1.474 billion yuan [2] - The sector's overall capital flow indicates a mixed sentiment among different investor types [2] Individual Stock Capital Flow - Notable capital flows included: - Huada Gene (300676) with a net inflow of 63.2761 million yuan from institutional investors [3] - Baicheng Pharmaceutical (301096) with a net inflow of 21.5534 million yuan from institutional investors [3] - Nanmo Biology (688265) saw a net outflow of 1.597 million yuan from institutional investors [3]

Investment Rating - The report does not provide specific ratings for the pharmaceutical industry, but indicates a neutral outlook for certain segments such as biopharmaceuticals and other pharmaceutical therapies [2]. Core Insights - The pharmaceutical industry is showing signs of stabilization and recovery, with a clear upward trend in performance [12]. - The CXO sector achieved a revenue of 47.096 billion yuan in the first half of 2025, representing a year-on-year growth of 13.25%, and a net profit of 11.743 billion yuan, up 61.19% year-on-year [12][10]. - The report highlights improvements in operational efficiency and cost reduction as key factors driving profit growth [12]. Summary by Sections 1. Industry Overview - The industry is gradually stabilizing, with a clear trend towards recovery. The CXO sector's revenue and profit have shown significant growth in the first half of 2025 [12][10]. - The average revenue per employee increased to 411,100 yuan, a year-on-year increase of 12.62%, while average profit per employee rose to 114,000 yuan, up 52.41% [4][25]. 2. Demand and Supply Dynamics - Demand is stabilizing with a slight recovery in orders, as indicated by a 3.71% year-on-year increase in contract liabilities and prepayments, reaching 7.549 billion yuan in the first half of 2025 [4][33]. - Supply-side indicators show a modest increase in capacity construction, with fixed assets growing by 5.81% year-on-year to 47.274 billion yuan [36]. 3. Financial Environment - The report notes the commencement of a Federal Reserve rate-cutting cycle, which is expected to enhance market liquidity [5][42]. - The A+H share innovation drug index has seen significant increases, which may positively influence local financing conditions [5]. 4. Company Recommendations - The report suggests focusing on clinical CROs benefiting from domestic innovation drug support policies, such as Yangguang Nuohuo and Nuosige [61]. - It also highlights companies with strong overseas business prospects, like Haoyuan Pharmaceutical and Bide Pharmaceutical, as well as those involved in weight loss drugs and Alzheimer's treatments [61]. 5. Performance Forecasts - For the company Hongbo Pharmaceutical, revenue is projected to grow from 739 million yuan in 2025 to 1.299 billion yuan by 2027, with a corresponding net profit increase [66]. - Haoyuan Pharmaceutical is expected to achieve revenues of 28.48 billion yuan by 2027, reflecting a growth rate of 25.47% [70]. 6. Market Trends - The CXO index has significantly outperformed the market, with a year-to-date increase of 58.32% as of September 11, 2025 [54]. - The report emphasizes the importance of monitoring changes in U.S. interest rate policies and geopolitical factors affecting the industry [5].

北京市嘉源律师事务所 关于上海泓博智源医药股份有限公司 2025 年第二次临时股东大会的 法律意见书 Sh 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 ิ้ YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:上海泓博智源医药股份有限公司 北京市嘉源律师事务所 关于上海泓博智源医药股份有限公司 2025 年第二次临时股东大会的 法律意见书 嘉源(2025)-04-670 北京市嘉源律师事务所(以下简称"本所")接受上海泓博智源医药股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称 "《公司法》"》《上市公司股东会规则》(以下简称"《股东会规则》")等现行有效 的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以及《上 海泓博智源医药股份有限公司章程》(以下简称"《公司章程》")的有关规定,指 派本所律师对公司 2025年第二次临时股东大会(以下简称"本次股东大会")进 行见证,并依法出具本法律意见书。 泓 ...

上海泓博智源医药股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：301230 证券简称：泓博医药 公告编号：2025-053 特别提示： 1、本次股东大会不存在新增、修改、否决议案的情形； 2、本次股东大会不存在变更前次股东大会决议的情形； 3、本次股东大会采取现场投票与网络投票相结合的方式进行。 一、会议召开情况 1、会议通知方式：公告方式 2、会议召开时间： （1）现场会议召开时间：2025 年 9 月 15 日（星期一）14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 15 日上午 9:15~9:25，9:30~11:30 和下午 13:00~15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为 2025 年 9 月 15 日 9:15～15:00 任意时间。 3、现场会议地点：上海浦东新区凯庆路 59 号 12 幢公司一楼会议室 4、会议召开方式：本次股东大会采取现场投票、网络投票相结合的方式。 参加本次股东大会表决的股东（含代 ...

Company Overview - Hongbo Pharmaceutical, established on December 14, 2007, is located at 59 Kaiqing Road, Pudong New District, Shanghai. The company was listed on November 1, 2022. Its main business involves drug discovery, pharmaceutical process research and development, and commercial production of raw material intermediates [1]. Business Revenue Composition - The revenue composition of Hongbo Pharmaceutical is as follows: drug discovery accounts for 52.67%, commercial production for 35.00%, process research and development for 8.10%, and other supplementary activities for 4.23% [1]. Stock Performance - On September 9, Hongbo Pharmaceutical's stock fell by 5.02%, closing at 36.33 CNY per share, with a trading volume of 213 million CNY and a turnover rate of 7.45%. The total market capitalization is 5.071 billion CNY [1]. Major Shareholders - Among the top ten circulating shareholders of Hongbo Pharmaceutical, a fund under China Europe Fund ranks as a significant holder. The China Europe Science and Technology Innovation Theme Mixed Fund (LOF) A (501081) entered the top ten shareholders in the second quarter, holding 1.1669 million shares, which is 1.52% of the circulating shares. The estimated floating loss today is approximately 2.2404 million CNY [2]. Fund Performance - The China Europe Science and Technology Innovation Theme Mixed Fund (LOF) A (501081) was established on June 28, 2019, with a latest scale of 2.238 billion CNY. Year-to-date returns are 51.39%, ranking 521 out of 8179 in its category. Over the past year, returns are 125.21%, ranking 140 out of 7984, and since inception, returns are 171.27% [2]. Fund Management - The fund manager of the China Europe Science and Technology Innovation Theme Mixed Fund (LOF) A (501081) is Jiejie Shao. As of the report date, Shao has been in the position for 5 years and 210 days, managing a total fund asset size of 9.284 billion CNY. The best fund return during the tenure is 114.56%, while the worst return is 0.58% [3].

中信证券股份有限公司 关于上海泓博智源医药股份有限公司 2025年半年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：泓博医药 | | --- | --- | | 保荐代表人姓名：王琦 | 联系电话：010-60833007 | | 保荐代表人姓名：李嵩 | 联系电话：010-60838329 | 2 11.其他需要说明的保荐工作情况 无 二、保荐人发现公司存在的问题及采取的措施 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | | 保荐人查阅了公司信息披露文件，深圳证券 | | | | 交易所互动易网站披露信息，重大信息的传 | | | 1.信息披 | 递披露流程文件，内幕信息管理和知情人登 | 不适用 | | 露 | 记管理情况，信息披露管理制度，检索公司 | | | | 舆情报道，对高级管理人员进行访谈，未发 | | | | 现公司在信息披露方面存在重大问题。 | | | 2.公司内 | 保荐人查阅了公司章程及内部制度文件，对 | | | 部制度的 | 公司高级管理人员进行访谈，未发现公司在 | 不适用 | | 建立和执 | 公司内部制度的建 ...

Market Performance - On September 5, the AI medical sector rose by 1.53%, with Yaoshi Technology leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - The top-performing stocks in the AI medical sector included: - Yaoshi Technology (300725) with a closing price of 44.21, up 3.85% [1] - ZheShu Culture (600633) with a closing price of 14.44, up 3.74% [1] - MaiDi Technology (603990) with a closing price of 14.64, up 3.24% [1] - Other notable stocks included Hongbo Pharmaceutical (301230) at 37.89, up 3.21%, and Jiahe Meikang (688246) at 31.20, up 2.80% [1] Capital Flow - The AI medical sector saw a net inflow of 56.49 million yuan from institutional investors, while retail investors experienced a net outflow of 50.12 million yuan [2] - The capital flow for specific stocks showed: - Meinian Health (002044) had a net inflow of 39.11 million yuan from institutional investors [3] - MaiDi Technology (603990) had a net inflow of 19.26 million yuan from institutional investors [3] - ZheShu Culture (600633) had a net inflow of 5.19 million yuan from institutional investors [3]